Journal
SEMINARS IN CANCER BIOLOGY
Volume 16, Issue 6, Pages 436-443Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2006.09.005
Keywords
thioredoxin; thioredoxin-binding proteins; histone deacetylase; histone deacetylase inhibitors; suberoylanilide hydroxamic acid
Categories
Funding
- NCI NIH HHS [P30 CA008748-23, CA-0974823, P30 CA008748] Funding Source: Medline
Ask authors/readers for more resources
Increased levels of thioredoxin (Trx) occur in a number of human cancers, which may contribute to the resistance of cancers to therapy by scavenging reactive oxygen species (ROS) which are generated by various anti-cancer agents. Many human cancers have low levels of thioredoxin-binding protein (TBP-2). TBP-2 binds to Trx and blocks its reducing activity. Histone deacetylase inhibitors (HDACi) up-regulate TBP-2 in various transformed cells, associated with a decrease in Trx levels. Up-regulation of TBP-2 and decrease of Trx may contribute to the sensitivity of many hematologic and solid tumors to anti-cancer activity of HDACi. (c) 2006 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
